Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Nexstim on its dual listing on First North Finland and First North Sweden
Mandate

Vinge advises Nexstim on its dual listing on First North Finland and First North Sweden

November 14, 2014

Vinge advised Nexstim on its IPO and dual listing of shares on First North Finland and First North Sweden. In the IPO, Nexstim issued 2,408,339 news shares at a subscription price of EUR 6.35 per share, amounting to gross proceeds of roughly EUR 15.3 million. Trading in the company's shares on First North Finland and First North Sweden commenced on 14 November 2014. The transaction is the first ever dual listing on the First North exchanges maintained by Nasdaq.

Nexstim is a medical technology company based in Finland that aims to improve rehabilitation for stroke patients. 

Vinge’s team primarily consisted of Jesper Schönbeck, Joakim Hagberg, Tora Hansjons and Nils Fredrik Dehlin.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024